Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Assets: 2011-2024

Historic Assets for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $488.7 million.

  • Adma Biologics' Assets rose 45.59% to $568.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $568.7 million, marking a year-over-year increase of 45.59%. This contributed to the annual value of $488.7 million for FY2024, which is 48.45% up from last year.
  • According to the latest figures from FY2024, Adma Biologics' Assets is $488.7 million, which was up 48.45% from $329.2 million recorded in FY2023.
  • In the past 5 years, Adma Biologics' Assets ranged from a high of $488.7 million in FY2024 and a low of $207.7 million during FY2020.
  • For the 3-year period, Adma Biologics' Assets averaged around $388.8 million, with its median value being $348.5 million (2022).
  • Per our database at Business Quant, Adma Biologics' Assets dropped by 5.53% in 2023 and then skyrocketed by 48.45% in 2024.
  • Adma Biologics' Assets (Yearly) stood at $207.7 million in 2020, then surged by 33.02% to $276.3 million in 2021, then climbed by 26.14% to $348.5 million in 2022, then declined by 5.53% to $329.2 million in 2023, then skyrocketed by 48.45% to $488.7 million in 2024.